AstraZeneca announces changes to Senior Executive Team

Tools


Tuesday, 15 January 2013

AstraZeneca today unveiled changes to its executive leadership team. The new, expanded membership of AstraZeneca's Senior Executive Team, which comes into effect immediately, includes increased representation of the company's scientific expertise, key products and key markets.

The changes include the creation of:

    Three senior research and development roles responsible for discovery and early stage development in small molecules; discovery and early stage development in biologics; and late stage development.
    Three roles representing the commercial regions: North America, Europe and International.
    A role responsible for global portfolio and product strategy, bridging between the R&D and sales organisation.

As a result of the changes, two senior roles – President of Research and Development, held by Martin Mackay, and Executive Vice President, Global Commercial, held by Tony Zook – have been eliminated. Martin Mackay and Tony Zook will leave the company at the end of January.

The full Senior Executive Team is as follows:

    Pascal Soriot Chief Executive Officer and Executive Director
    Simon Lowth Chief Financial Officer and Executive Director
    Mene Pangalos Executive Vice President, Innovative Medicines
    Bahija Jallal Executive Vice President, MedImmune
    Briggs Morrison Executive Vice President, Global Medicines Development
    Paul Hudson Executive Vice President, North America
    Ruud Dobber Executive Vice President, Europe
    Mark Mallon Executive Vice President, International
    David Smith Executive Vice President, Operations & IS
    Lynn Tetrault Executive Vice President, Human Resources & Corporate Affairs
    Katarina Ageborg Chief Compliance Officer
    Jeff Pott General Counsel

The appointment of Executive Vice President, Global Portfolio & Product Strategy will be made at a later date.

Pascal Soriot, Chief Executive Officer, said: "This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets, and helps us further accelerate decision-making."

Commenting on Martin Mackay and Tony Zook, Pascal Soriot said: "I would like to thank Martin and Tony for their contribution and the exemplary leadership they have shown in their time at AstraZeneca. We wish them well in their future endeavours."

Details of AstraZeneca's Senior Executive Team, including biographies, can be found on the company's web site at www.astrazeneca.com/About-Us/Board-and-management
NOTES TO EDITORS
About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries UK

Esra Erkal-Paler +44 20 7604 8030
Vanessa Rhodes +44 20 7604 8037
Media Enquiries US

Tony Jewell +1 302 885 4594
Media Enquiries Sweden

Ann-Leena Mikiver +46 8 553 260 20
Investor Enquiries

James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Colleen Proctor +1 302 886 1842 mob: +1 302 357 4882